​

Bio-Techne (TECH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TECH Stock Forecast

Bio-Techne (TECH) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $66.44, with a high of $79.00 and a low of $50.00. This represents a -7.21% decline from the last price of $71.60.

$50 $57 $64 $71 $78 $85 High: $79 Avg: $66.44 Low: $50 Last Closed Price: $71.6

TECH Stock Rating

Bio-Techne stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (50.00%), 13 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 26 0 13 13 Strong Sell Sell Hold Buy Strong Buy

TECH Price Target Upside V Benchmarks

TypeNameUpside
StockBio-Techne-7.21%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-917
Avg Price Target-$63.11$66.18
Last Closing Price$71.60$71.60$71.60
Upside/Downside--11.86%-7.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 261311--15
Jun, 26294--15
May, 26194--14
Apr, 26194--14
Mar, 261104--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 26, 2026Steven EtochStephens$73.00$71.162.59%1.96%
Jun 26, 2026Catherine Ramsey SchulteRobert W. Baird$73.00$70.703.25%1.96%
Jun 26, 2026Justin BowersDeutsche Bank$73.00$70.703.25%1.96%
Jun 25, 2026Market PerformLeerink Partners$73.00$70.553.47%1.96%
Jun 11, 2026Piper Sandler$65.00$52.5023.81%-9.22%
May 14, 2026RBC Capital$62.00$44.7438.58%-13.41%
May 07, 2026Daniel MarkowitzEvercore ISI$50.00$49.271.48%-30.17%
May 07, 2026Stifel Nicolaus$50.00$47.415.46%-30.17%
May 07, 2026Robert W. Baird$49.00$47.413.35%-31.56%
Feb 05, 2026Stifel Nicolaus$65.00$67.64-3.90%-9.22%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 09, 2026RBC CapitalOutperformSector Performdowngrade
Jun 30, 2026BenchmarkBuyHolddowngrade
Jun 29, 2026Cowen & Co.BuyHolddowngrade
Jun 26, 2026CitigroupBuyNeutraldowngrade
Jun 26, 2026Deutsche BankBuyHolddowngrade
Jun 25, 2026William BlairOutperformMarket Performdowngrade
Jun 23, 2026Cowen & Co.BuyBuyhold
Jun 11, 2026Piper SandlerNeutralinitialise
Mar 17, 2026Cowen & Co.BuyBuyhold
Feb 05, 2026Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28
Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28
Reported$1.73$1.81$1.07----
Avg Forecast$1.98$2.00$1.78$1.88$2.18$2.49-
High Forecast$2.01$2.05$1.80$1.92$2.35$2.80-
Low Forecast$1.94$1.96$1.76$1.83$2.04$2.28-
Surprise %-12.63%-9.50%-39.89%----

Revenue Forecast

$1B $1B $1B $2B $2B $2B Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28
Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28
Reported$1.11B$1.14B$1.16B----
Avg Forecast$1.10B$1.14B$1.16B$1.22B$1.33B$1.48B$1.86B
High Forecast$1.12B$1.16B$1.18B$1.23B$1.36B$1.48B$1.89B
Low Forecast$1.09B$1.12B$1.14B$1.21B$1.31B$1.47B$1.83B
Surprise %0.05%-0.54%0.02%----

Net Income Forecast

Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28
Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28
Reported$272.05M$285.26M$168.10M----
Avg Forecast$196.47M$321.71M$150.68M$300.71M$352.85M$408.30M-
High Forecast$235.76M$329.07M$180.82M$308.01M$377.54M$450.83M-
Low Forecast$157.18M$315.03M$120.54M$293.42M$328.15M$365.77M-
Surprise %38.47%-11.33%11.56%----

TECH Forecast FAQ

Is Bio-Techne stock a buy?

Bio-Techne stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 13 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bio-Techne is a favorable investment for most analysts.

What is Bio-Techne's price target?

Bio-Techne's price target, set by 26 Wall Street analysts, averages $66.44 over the next 12 months. The price target range spans from $50 at the low end to $79 at the high end, suggesting a potential -7.21% change from the previous closing price of $71.6.

How does Bio-Techne stock forecast compare to its benchmarks?

Bio-Techne's stock forecast shows a -7.21% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Bio-Techne over the past three months?

  • July 2026: 6.67% Strong Buy, 20.00% Buy, 73.33% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 13.33% Strong Buy, 60.00% Buy, 26.67% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 7.14% Strong Buy, 64.29% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.

What is Bio-Techne’s EPS forecast?

Bio-Techne's average annual EPS forecast for its fiscal year ending in June 2025 is $1.88, marking a 75.70% increase from the reported $1.07 in 2024. Estimates for the following years are $2.18 in 2026, $2.49 in 2027, and $0 in 2028.

What is Bio-Techne’s revenue forecast?

Bio-Techne's average annual revenue forecast for its fiscal year ending in June 2025 is $1.22B, reflecting a 5.28% increase from the reported $1.16B in 2024. The forecast for 2026 is $1.33B, followed by $1.48B for 2027, and $1.86B for 2028.

What is Bio-Techne’s net income forecast?

Bio-Techne's net income forecast for the fiscal year ending in June 2025 stands at $300.71M, representing an 78.88% increase from the reported $168.1M in 2024. Projections indicate $352.85M in 2026, $408.3M in 2027, and $0 in 2028.